Pharmaco - Press Releases

Date	Title	Company
09-Dec-2019	Athira Pharma Presents Positive Data for NDX-1017 in Alzheimer's Patients at 2019 Clinical Trials on Alzheimer's Disease (CTAD) Conference	Athira Pharma, Inc.
09-Dec-2019	CNS Pharmaceuticals to Participate in the 8th Annual ROTH Deer Valley Corporate Access Event	CNS Pharmaceuticals, Inc.
09-Dec-2019	InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa	InMed Pharmaceuticals Inc.
09-Dec-2019	Actinium Pharmaceuticals Announces Phase 3 SIERRA Trial Dosimetry Results Support Low Dose Iomab-B for Targeted Lymphodepletion Prior to Adoptive Cell Therapy	Actinium Pharmaceuticals, Inc.
09-Dec-2019	IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020	IDEAYA Biosciences, Inc.
09-Dec-2019	AEVIS VICTORIA SA: Sale of Générale Beaulieu Immobilière SA to Infracore SA	AEVIS VICTORIA SA
09-Dec-2019	Medartis provides update on Brazil investigation	Medartis Holding AG
08-Dec-2019	Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting	Eli Lilly and Company
08-Dec-2019	Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies	Portola Pharmaceuticals, Inc.®
08-Dec-2019	Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting	Viracta Therapeutics, Inc.
08-Dec-2019	New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)	AbbVie
07-Dec-2019	Oncopeptides Presents Updated Efficacy and Safety Data from Pivotal Phase 2 HORIZON Study in Patients With RRMM at ASH Annual Meeting 2019	Oncopeptides AB
07-Dec-2019	Janssen to Acquire Investigational Bermekimab from XBiotech	Janssen Pharmaceutical Companies of Johnson & Johnson
06-Dec-2019	Grifols presents its latest Alzheimer's clinical trial data	Grifols
06-Dec-2019	LPCN INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Lipocine Inc.	Bernstein Liebhard LLP
06-Dec-2019	LPCN INVESTOR ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Lipocine Inc.	Bernstein Liebhard LLP
06-Dec-2019	Inland Empire Health Plan (IEHP) Passes CMS Formulary Review	IEHP
06-Dec-2019	Curis Announces Positive Safety, Tolerability and Pharmacokinetic Data in Ongoing Phase 1 Study of Fimepinostat in Combination with Venetoclax	Curis, Inc.
06-Dec-2019	Bimekizumab Phase 3 Psoriasis Study Demonstrates Superiority Versus Humira®	UCB, Inc.
06-Dec-2019	VERFORA awarded European Launch of the Year	VERFORA